QR Code

Oral FXIIa inhibitor KV998086 suppresses FXIIa and single chain FXII mediated kallikrein kinin system activation

Background: The kallikrein kinin system (KKS) is an established pharmacological target for the treatment and prevention of attacks in hereditary angioedema (HAE). Proteolytic activities of FXIIa and single-chain Factor XII (FXII) zymogen contribute to KKS activation and thereby may play roles in bot...

Whakaahuatanga katoa

I tiakina i:
Ngā kaituhi matua: Allen C. Clermont, Nivetha Murugesan, Hannah J. Edwards, Daniel K. Lee, Natasha P. Bayliss, Edward J. Duckworth, Stephen J. Pethen, Sally L. Hampton, David Gailani, Edward P. Feener
Hōputu: Artigo
Reo:Inglês
I whakaputaina: Frontiers Media S.A. 2023-12-01
Rangatū:Frontiers in Pharmacology
Ngā marau:
factor XIIa inhibitor
FXII zymogen
hereditary angioedema
kallikrein-kinin system
HAE
Urunga tuihono:https://www.frontiersin.org/articles/10.3389/fphar.2023.1287487/full
Ngā Tūtohu: Tāpirihia he Tūtohu
Kāore He Tūtohu, Me noho koe te mea tuatahi ki te tūtohu i tēnei pūkete!

Ngā tūemi rite